tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Allarity Therapeutics’ Stenoparib Shows Promise in Ovarian Cancer Trial

Allarity Therapeutics’ Stenoparib Shows Promise in Ovarian Cancer Trial

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Allarity Therapeutics, Inc. (ALLR) has provided an announcement.

Allarity Therapeutics, Inc. has announced a significant breakthrough with its drug stenoparib, as it has shown clear clinical benefits in a Phase 2 trial for treating advanced recurrent ovarian cancer, leading to an early conclusion of the study. This development marks a notable milestone in the company’s endeavors to advance cancer treatment.

For detailed information about ALLR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1